The case highlights how mergers involving EOU pharmaceutical entities demand approvals under GST, DGFT, Customs, and sectoral laws. The key takeaway is that EOU benefits survive only with prior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback